News from BAT Research & Development
British American Tobacco’s Award Winning 2017/18 Science & Technology Report explores the evolution of tobacco science and highlights our world class alternatives to smoking. It also reinforces our commitment to providing open and transparent communications around our non-competitive science.
BAT has won the award for the ‘Most Impressive Public Service Initiative’ at the Global Tobacco and Nicotine Forum (GTNF) conference in Brussels.
Scientists at British American Tobacco used lab-based cellular tests to examine the impact of cigarette smoke and Vype e-cigarette vapour on human lung cells.
‘Bespoke’ study designs central to assessment of next-generation products, British American Tobacco scientists tell NAS
Dr Marianna Gaca and Dr James Murphy were both invited to present at the National Academy of Sciences in Washington DC last week, at a committee reviewing the health effects of Electronic Nicotine Delivery Systems (ENDS).
New research shows that at equivalent or higher doses of nicotine, acute exposure to e-cigarette vapour has very limited impact on gene expression compared to cigarette smoke.
Two new Adverse Outcome Pathways (AOPs), developed jointly by British American Tobacco (BAT) and Philip Morris International (PMI), are featured in a special issue of Applied In Vitro Toxicology (AIVT) focusing on the in vitro evaluation of next-generation nicotine products.